Ureas

Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data from Sweden

Retrieved on: 
Thursday, December 17, 2020
Collagen disease, Contortion, Celiprolol, Ureas, Anatomy, Branches of biology, Medical specialties, Ehlers

The publication, entitled Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome,1 can be found at https://www.ejves.com/action/showPdf?pii=S1078-5884%2820%2930930-8 .

Key Points: 
  • The publication, entitled Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome,1 can be found at https://www.ejves.com/action/showPdf?pii=S1078-5884%2820%2930930-8 .
  • Patients were followed for a median of 22 months (range 1-98 months) with a total follow up of 106 patient years.
  • Sixty-five percent of the patients reached the target dose of 400 mg and the medication was generally well tolerated.
  • Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.

The New Normal: Protect Yourself with Face Masks, & Protect Your Skin with the InnerB System® Inner Mask

Retrieved on: 
Wednesday, December 2, 2020
Chemistry, Physical sciences, Natural sciences, Allantoin, Excipients, Hydantoins, Ureas, Face mask, Skin mask, Mask, Hydrogel

To control breakouts and irritation caused by face masks, Aquavit is launching the SKINWORKOUT InnerB System I nner Mask for Blemish Control using its hydrogel technology .

Key Points: 
  • To control breakouts and irritation caused by face masks, Aquavit is launching the SKINWORKOUT InnerB System I nner Mask for Blemish Control using its hydrogel technology .
  • Aquavit secured its inventive rights of PPE-ready inner mask with a worldwide patent process early this year.
  • The skin mask also contains Allantoin, Ulmus Davidiana Root extract, Centraria Islandica extract, and other natural ingredients that soothe and hydrate the skin.
  • The Inner B System Inner Mask is composed of 2 pieces, separated for upper and lower portions of the face.

AVEO Oncology to Present at the Stifel 2020 Virtual Healthcare Conference

Retrieved on: 
Tuesday, November 10, 2020
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Cars, Chemical compounds, Organic compounds, Ureas, Isoxazoles, Quinolines, Tivozanib, Chevrolet Aveo

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time.
  • A live webcast of the presentation can be accessed by visiting the investors section of the Companys website at www.aveooncology.com .
  • AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.
  • AVEO is working to develop and potentially commercialize tivozanib in the U.S. as a treatment for renal cell carcinoma and hepatocellular carcinoma.

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Versus Sunitinib as First-Line Treatment for Patients…

Retrieved on: 
Tuesday, November 10, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Cancer treatments, Drugs, Orphan drugs, Antineoplastic drugs, Chloroarenes, Ureas, Breakthrough therapy, Pembrolizumab, Everolimus, Sorafenib, Merkel-cell carcinoma, KEYNOTE-581/CLEAR (Study 307), LENVIMA® (lenvatinib) Capsules, Merck, Eisai

The safety profiles of both KEYTRUDA plus LENVIMA and LENVIMA plus everolimus were consistent with previously reported studies.

Key Points: 
  • The safety profiles of both KEYTRUDA plus LENVIMA and LENVIMA plus everolimus were consistent with previously reported studies.
  • The results from KEYNOTE-581/CLEAR (Study 307) support the potential use of KEYTRUDA plus LENVIMA for the first-line treatment of advanced RCC.
  • KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program by Clinical and Translational Science Journal

Retrieved on: 
Tuesday, November 3, 2020
Chemistry, Organic compounds, Chemical compounds, HIV protease inhibitors, Ureas, Hepatotoxins, Clinical Pharmacology & Therapeutics, Lopinavir, Favipiravir, Remdesivir, Clinical Pharmacology: Advances and Applications, Ritonavir

CTS highlights original research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease and is an official journal of the American Society of Clinical Pharmacology and Therapeutics (ASCPT).

Key Points: 
  • CTS highlights original research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease and is an official journal of the American Society of Clinical Pharmacology and Therapeutics (ASCPT).
  • We are honored to be sharing this peer-reviewed manuscript in an internationally acclaimed journal, said George Yeh, President of TLC.
  • CTS has a collection of clinical pharmacology research from various potential treatments such as remdesivir, favipiravir, and lopinavir/ritonavir.
  • Acknowledgment of our work by CTS further fortifies the soundness of our strategy of preferential delivery to the lungs.

Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020

Retrieved on: 
Monday, November 2, 2020
Chemical compounds, Chemistry, Organic compounds, Ethers, GnRH antagonists, Triketones, Pyrimidines, Relugolix, Ureas, Prostate cancer, Conjugated estrogens

The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on November 12, 2020.

Key Points: 
  • The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on November 12, 2020.
  • Investors and the general public may access a live webcast of the call by visiting the investor relations page of Myovants website at investors.myovant.com .
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.
  • Relugolix monotherapy tablet (120 mg) is under regulatory review in theU.S.for men with advanced prostate cancer.

Rediscovery Life Sciences Completes $4.5M Series B Financing

Retrieved on: 
Wednesday, September 23, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, RTT, Anthelmintics, In science, Suramin, Ureas, Medical University of South Carolina, Aki, Drugs, Chemistry, Acute Kidney Injury, Rediscovery Life Sciences and suramin

Rediscovery Life Sciences, LLC (RLS), a clinical-stage biotechnology company, announced the closing of its most recent financing.

Key Points: 
  • Rediscovery Life Sciences, LLC (RLS), a clinical-stage biotechnology company, announced the closing of its most recent financing.
  • The Series B financing was co-led by REX Health Ventures (the investment arm of UNC REX Healthcare) and Orlando Health Ventures.
  • RLS is focused on rapid and cost-effective development of new treatments by identifying and repurposing existing drugs with strong safety profiles.
  • Rediscovery Life Sciences has executed an exclusive license with The Medical University of South Carolina (MUSC) to develop suramin in acute kidney injury (AKI).

Searchlight Pharma expands its Women's Health Portfolio and initiates Addyi® commercial activities

Retrieved on: 
Wednesday, September 16, 2020
Human sexuality, Aphrodisiacs, Benzimidazoles, Flibanserin, Ureas, Hypoactive sexual desire disorder, Pharmaceutical industry in China, Searchlight

Searchlight Pharma acquired the Canadian rights to Addyi (flibanserin) via its recently executed licensing transaction with Sprout Pharmaceuticals.

Key Points: 
  • Searchlight Pharma acquired the Canadian rights to Addyi (flibanserin) via its recently executed licensing transaction with Sprout Pharmaceuticals.
  • Following just weeks after its recently executed long term licensing agreement with Sprout Pharmaceuticals, Searchlight Pharma will now integrate Addyi into its industry-leading women's health and female sexual health portfolio deploying its national salesforce to promote this novel brand.
  • "We are excited to further grow our women's health portfolio with this first-in-class medication for the treatment of HSDD in Canada," said Mark Nawacki, President and CEO of Searchlight Pharma.
  • We couldn't think of a better partner than Searchlight considering their impressive track record and steadfast commitment to women's health."

AVEO Oncology Announces European Urology Publication of Final Overall Survival Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

Retrieved on: 
Tuesday, September 15, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Chemical compounds, Organic compounds, Cancer treatments, Ureas, Pyridines, Angiogenesis inhibitors, Chloroarenes, Sorafenib, Tivozanib, Hepatocellular carcinoma, Renal cell carcinoma, Evofosfamide, Tivozanib (FOTIVDA, AVEO Pharmaceuticals, Inc.

AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology.
  • The article, titled Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma, is available online first via this link .
  • We expect that Tivozanibs TIVO-3 data has the potential to guide important treatment decisions in this setting and ultimately improve outcomes and patient experience.
  • AVEO is working to develop and potentially commercialize tivozanib in North America as a treatment for renal cell carcinoma and hepatocellular carcinoma.

AVEO Oncology Announces Participation at Two Upcoming Investor Conferences

Retrieved on: 
Thursday, September 3, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Clinical medicine, Medicine, Chemical compounds, Isoxazoles, Quinolines, Tivozanib, Ureas, Immunology, Aveos Fleet Performance, Monoclonal antibody

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences:

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences:
    A live webcast of the events can be accessed by visiting the investors section of the Companys website at www.aveooncology.com .
  • AVEO is developing an oncology pipeline designed to provide a better life for patients with cancer.
  • AVEO is working to develop and commercialize tivozanib in North America as a treatment for renal cell carcinoma and hepatocellular carcinoma.
  • AVEOs earlier-stage pipeline includes several monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb), AV-380 (anti-GDF15 mAb) and AV-353 (anti-Notch 3 mAb).